1.Comparison of Plasma N-Terminal Pro-B-Type Natriuretic Peptide Levels Between European and Japanese Patients with Acute Heart Failure:An International Study
Jolie BRUNO ; Aziz DAGHMOURI ; Ayu ASAKAGE ; Camille GOBEAUX ; Kamilė ČERLINSKAITĖ-BAJORĖ ; Jelena ČELUTKIENĖ ; Naoki SATO ; Koji TAKAGI ; Alexandre MEBAZAA ; Benjamin DENIAU ; Shiro ISHIHARA
Annals of Laboratory Medicine 2026;46(3):338-344
Plasma biomarkers levels, essential for diagnosing cardiovascular diseases, may vary by ethnicity. In this international prospective study, we compared plasma biomarker levels between European and Asian patients with clinically similar acute heart failure (AHF). Data were collected on emergency admission for acute dyspnea. Blood samples were obtainedwithin 4 hrs of presentation and analyzed for N-terminal pro-B-type natriuretic peptide (NTproBNP), high-sensitivity troponin-T, growth differentiation factor 15, interleukin-6, and C-reactive protein levels. Overall, 907 AHF patients were enrolled; of which, 135 (15%) wereJapanese, and 772 (85%) were European. NT-proBNP levels were significantly higher inHôpital Lariboisière, Bat Viggo Petersen, Porte 5 au 2ème étage, 43 boulevard de la chapelle, Paris 75010, FranceJapanese than in Europeans [4,060 ng/L (interquartile range (IQR) 2,081–12,218) vs.3,390 ng/L (IQR 1,410–7,682), P = 0.004]. After propensity score matching (PSM), no bio-marker levels differed significantly. After stratification according to left ventricular ejection fraction (LVEF) at admission, higher NT-proBNP levels were observed in Japanese AHF pa-tients with LVEF > 50% (P = 0.02) than in European patients. After PSM, the difference was insignificant (P = 0.35). In Asian and Caucasian AHF patients with similar clinical profiles, plasma cardiovascular biomarker levels did not differ significantly, regardless of LVEF, sug-gesting that NT-proBNP and related biomarkers can be applied across these ethnicities.
2.Regular Health Consultations for Elderly People Living in Housing Complexes through Multidisciplinary Collaboration Led by Health Support Pharmacy
Juna ESHITA ; Kazuhiko ONO ; Mamiko KAI ; Ei SEJIMA ; Mayo TAKAGI ; Ai IMOTO ; Haruka SONOKI ; Takamasa MIISHO ; Kunihiro WATANABE ; Kousuke KITAKE ; Takeshi OOE ; Soichiro USHIO ; Toshinobu HAYASHI ; Koji TOMINAGA ; Takashi EGAWA
An Official Journal of the Japan Primary Care Association 2025;48(2):77-81
3.Effects of a Mouthwash Containing Plant Extracts on Gingivitis and Halitosis
Koji HATTORI ; Akiko WATANABE ; Hiroshi TAKAGI ; Naokazu HOTTA ; Youichi YASHIRO ; Ryoma GOTO ; Noritaka SAWADA ; Genta YAMAMOTO ; Akio MITANI ; Seiji HASEGAWA
Japanese Journal of Complementary and Alternative Medicine 2023;20(1):1-8
Mouthwash is used to support brushing because it is distributed throughout the oral cavity. In this study, we examined the efficacy of a mixture of three hot water extracts (from Hordeum vulgare L, Apocynum venetum L, and Brasenia schreberi J. F. Gmel) for the purpose of developing an effective mouthwash. The mixture suppressed enhanced tumor necrosis factor α and matrix metalloproteinase 3 gene expression by Porphyromonas gingivalis lipopolysaccharide stimulation in human gingival fibroblasts. Furthermore, human studies using a mouthwash containing the plant extracts (MW) improved gingival index and bleeding on probing in the gum, and reduced the concentration of methyl mercaptan, which causes bad breath, in the mouth. These findings suggest that continued use of MW has positive effects on gingival inflammation and halitosis, and is useful for maintaining oral health.
4.Experience in Using Jumihaidokuto and Orengedokuto for Skin Disorders Caused by Molecular Target Drugs
Koki MORI ; Tatsuya HIROSE ; Koji TANAKA ; Atsuko TAKEDA ; Masahiro UNO ; Hajime TAKAGI
Kampo Medicine 2020;71(1):30-35
In some molecular targeted therapies, skin disorders including acne-like rashes or maculopapular rashes frequently appear, which are often clinically problematic. In Kampo medicine, it has been reported that the combination of jumihaidokuto and orengedokuto (hereinafter called JHT + OGT) is effective for acne. In this study, we report the experiences of JHT + OGT for the treatment of rashes caused by molecular targeted therapies. We extracted patients from June 2013 to June 2017 who took molecular targeted therapies and the treatment with JHT + OGT for skin rashes. The primary endpoint was severity of rashes before and after treatment by JHT + OGT (judged by CTCAE v4.0). In 22 patients (14 males and 8 females), the rashes after treatment with JHT + OGT significantly improved compared with those before treatment (from the median grade of 2 to 1 [p = 0.011]), with 14 cases of improvement, 6 cases of no change, and 2 cases of deterioration. It was suggested that JHT + OGT for skin rashes caused by molecular targeted therapies could be one of the treatment options.
5.Improvement Effects of Dentifrice Containing Plant Extracts on Periodontal Disease
Koji HATTORI ; China SATO ; Hiroshi TAKAGI ; Youichi YASHIRO ; Hisashi GOTO ; Yuki SUZUKI ; Genta YAMAMOTO ; Akio MITANI ; Satoru NAKATA
Japanese Journal of Complementary and Alternative Medicine 2017;14(1):27-32
Effects of three plant extracts (Hordeum vulgare L., Apocynum Venetum L., Brasenia schreberi J.F.G mel.) on human gingival fibroblasts were examined. As a result, we observed the promoting effect of the extract of Hordeum vulgare L. and the extract of Apocynum Venetum L. respectively on FGF2 and FGF7 production. Moreover, the mixture of the three plant extracts showed the effect of improving the changes in type I collagen gene expression and matrix metalloproteinase 1 gene expression by LPS addition. Next, a dentifrice containing the three plant extracts was subjected to human efficacy trials. We measured periodontal pocket depth, attachment level, bleeding on probing and saliva TNFα as an indicator of periodontal disease. The results suggest that the dentifrice formulated with the three plant extracts were effective for the improvement of periodontal disease.
6.Laparoscopic Round Ligament Psoas Minor Tendon-Hitching: Newly Developed Uterine Prolapse Operation
Koji SHIMABUKURO ; Tamami ODAI ; Takanori YOSHIDA ; Takafumi TSUKADA ; Yukiko NUSHI ; Yasuko NISHIDA ; Kaori TAKAGI ; Reiko NAKAMURA ; Sanae HATTORI ; Naoyuki MIYASAKA ; Maiko ICHIKAWA ; Seiichi ENDO ; Masae SAKAMOTO
Journal of the Japanese Association of Rural Medicine 2016;64(5):815-818
We have developed a new surgical procedure for uterine prolapse of round ligament suspension to the psoas minor tendon by the use of a laparoscope. Here, we describe the new technique and report the outcome of surgery in three cases. Operative procedure: The fundus of the uterus is lifted back up to its natural position by fixing the round ligament of the uterus to the psoas minor tendon after incising the peritoneum covering psoas. It is important to use the tendon as a stronger reattachment site in addition to the psoas major muscle. The round ligament is tacked to the tendon by a 2-0 nonabsorbable suture on bilateral sides. The second suture may be added if the uterus is not appropriately lifted up by the first suture. The retroperioneum is closed by a continuous 3-0 absorbable suture after fixation. Cases: Two patients with severe uterine prolapse and one patient with a mild condition went through the operation safely and have experienced no recurrence for 10 to 24 months. One severely ill patient complained about post -operative right inguinal pain early and another with the severe condition complained that something felt wrong with the right thigh. We propose the operation of laparoscopic round ligament psoas minor tendon-hitching as a safe and effective surgical treatment for uterine prolapse.
7.A Case of Erythropoietin-secreting Large Uterine Leiomyoma
Yasuko NISHIDA ; Seiichi ENDO ; Kaori TAKAGI ; Yukiko NUSHI ; Reiko NAKAMURA ; Tamami ODAI ; Sanae HATTOR ; Maiko ICHIKAWA ; Masae SAKAMOTO ; Koji SHIMABUKURO ; Chigusa NAGATA
Journal of the Japanese Association of Rural Medicine 2016;65(2):244-249
A 59-year-old woman, para 2, attended our hospital for an abdominal mass and atypical genital bleeding. Magnetic resonance imaging revealed a 30×25cm uterine myoma. A preoperative blood examination showed the following results: hemoglobin, 21g/dl; hematocrit, 71.5%; erythropoietin, 38.5mIU/ml; and estradiol, 29.9pg/ml. Abdominal total hysterectomy and bilateral salpingo-oophorectomy were performed, with an estimated blood loss of 1650ml. The weight of the uterus, including the myoma nodule, was 4740g, and the results of histology confirmed the diagnosis of leiomyoma. By postoperative day 28, her hemoglobin, erythropoietin, and estradiol levels had fallen to levels of 15.1g/dl, 6.0mIU/ml, and 5.8pg/ml, respectively, which are normal for a postmenopausal woman. The findings suggest that the leiomyoma secreted erythropoietin and induced erythrocytosis. Estradiol stimulates erythropoietin secretion and enlargement of the leiomyoma. Some studies have shown that erythropoietin is also a growth factor for leiomyoma. More than half of the erythropoietin-producing leiomyomas are detected after menopause. It was discovered that leiomyoma cells can produce aromatase, which transforms androstenedione into estradiol. Although estradiol secretion from the ovaries decreases in the postmenopausal period, the estradiol and erythropoietin autocrine/paracrine system in leiomyoma might promote its own growth after menopause.
8.Study of Intrauterine Fetal Death after 22 Weeks of Gestation
Tamami ODAI ; Maiko ICHIKAWA ; Naoyuki MIYASAKA ; Kaori TAKAGI ; Yasuko NISHIDA ; Yukiko NUSHI ; Reiko NAKAMUARA ; Sanae HATTORI ; Seiichi ENDO ; Masae SAKAMOTO ; Koji SHIMABUKURO
Journal of the Japanese Association of Rural Medicine 2016;65(2):215-221
We researched intrauterine fetal death (IUFD) after 22 weeks of gestation from 2009 to 2014 in our departments. During this period, there were 6236 childbirths and 35 cases (0.56%) resulted in IUFD. We researched the background and causes of IUFD in these 35 cases. The median age was 34 years and advanced maternal age accounted for 48.6% of cases, while elderly primipara accounted for 20%. There were 5 cases (14.3%) of pregnancy after fertility treatment. The median gestational age when IUFD was recognized was 30 weeks, but the gestational age in 4 cases was unclear because of lack of antenatal check-ups. The main risk factors for IUFD were maternal age over 35 (0.95% to 0.40%) and lack of antenatal check-ups (3.7% to 0.5%). The major causes of IUFD were umbilical cord abnormalities (n=10) and placental abruption (n=8), but IUFD of unknown etiology accounted for about 30% of cases. We should better inform mothers about the importance of antenatal check-ups and manage pregnancies carefully for those who have risk factors for IUFD. Furthermore, we should increase research into the causes of stillbirths.
9.A Case of Deep Venous Thrombosis and Pulmonary Thrombosis during Week 29 of Pregnancy
Sanae HATTORI ; Maiko ICHIKAWA ; Shiori OKIKURA ; Haruka MANAYAMA ; Kaori TAKAGI ; Yasuko NISHIDA ; Yukiko NUSHI ; Reiko NAKAMURA ; Tamami ODAI ; Seiichi ENDO ; Masae SAKAMOTO ; Koji SHIMABUKURO
Journal of the Japanese Association of Rural Medicine 2016;65(4):857-861
A major cause of pulmonary thromboembolism (PTE) is deep venous thrombosis (DVT). We report here a case of DVT in a 31-year-old woman during week 29 of her second pregnancy. At week 29, the patient noticed swelling of the left leg and pain in the groin after sitting. At almost week 30, walking became difficult due to pain and she was referred to hospital. Computed tomography (CT) revealed a thrombus from the left common iliac vein to the femoral vein and multiple thrombi in the right pulmonary artery. Blood testing showed elevated D-dimer (3.4μg/ml). Continuous intravenous unfractionated heparin was administered, and the dose was increased due to decreased activated partial thromboplastin time control. Despite conservative therapy for DVT, the thrombi showed no change since admission. At almost week 37, a temporary inferior vena cava filter (t-IVCF) was placed to prevent pulmonary thromboembolism, and she had an uneventful delivery of a baby by Caesarean section. Warfarin was administered postpartum. The t-IVCF was removed 4 days after delivery, and the patient was discharged 10 days after delivery. Within the field of obstetrics, the need for IVCF insertion should be considered on an individual case basis and should not be viewed as a standard option.
10.Clinical Study of Catamenial Pneumothorax
Mayumi KOBAYASHI ; Takuya ONUKI ; Masaharu INAGAKI ; Yasuko NISHIDA ; Kaori TAKAGI ; Yoshihide SAGAWA ; Reiko NAKAMURA ; Tamami ODAI ; Yoko FUJIOKA ; Maiko ICHIKAWA ; Seiichi ENDO ; Masae SAKAMOTO ; Koji SHIMABUKURO
Journal of the Japanese Association of Rural Medicine 2015;64(1):56-60
Catamenial pneumothorax (CP) is defined as a form of thoracic endometriosis syndrome (TES) and the clinical manifestations and management of this disease are not consensual. Successful treatment depends on how closely pulmonary specialists and gynecologists work together. Such being the circumstances, we reviewed our experience with CP in terms of treatment and follow-up. We treated surgically many patients with pneumothorax during the period from 1989 to 2014, of which eight cases had endometriosis on the diaphragm, lung or pleura histologically. The median age at the time of operation was 37 (range, 17 to 41). CP was right-sided in seven of the eight patients (87.5%). Six patients underwent an examination with diagnostic laparoscopy and five had positive findings. The median period of follow-up after surgery was 33.5 months (range, 4 to 129 months). Two patients had no recurrence without hormonal therapy. Six other patients experienced a recurrence of pneumothorax, although two patients received dienogest after surgery. The use of only dienogest or both GnRHa and dienogest prevented recurrence in all patients. CP is a critical condition that requires prompt action, so after surgical treatment, the choice of hormonal therapy with a high rate of patient compliance are needed. No recurrence occurred in young patients who had only surgical treatment, suggesting that there were some associations between age and recurrence. Since we succeeded in preventing recurrence after using GnRHa in all cases, we recommend GnRHa or dienogest following GnRHa for the first choice of hormonal therapy after surgery. However, treatment with only dienogest could achieve successful results with no recurrence, so more case studies need to be done to make the best treatment choice for each case.


Result Analysis
Print
Save
E-mail